BMT2

Across TCGA pan-cancer cohorts, BMT2 RNA is linked to patient survival in 26 of 34 cancer types, making it the most broadly survival-associated BMT2 data layer compared with 1 for mutation status and 3 for mass-spec protein.

The strongest signal is observed in mesothelioma (MESO), where higher BMT2 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated BMT2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and KIRC show a favorable association.

MESO, LUAD, and KICH are the cancer types where BMT2 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	OS	Median	All	0.273	0.504	<.001	102	view →
LUAD	DFS	Quartile	All	0.837	0.716	.004	76	view →
KICH	DFS	Median	All	0.675	0.978	<.001	75	view →
KIRC	OS	Tertile	All	0.757	0.543	<.001	75	view →
BLCA	OS	Median	II,III,IV	0.665	0.751	.005	40	view →
LIHC	OS	Quartile	All	0.395	0.625	<.001	38	view →
UVM	DFS	Median	III,IV	0.208	0.740	.006	36	view →
OV	OS	Tertile	All	0.646	0.730	.006	30	view →
SCLC	DFS	Quartile	All	0.468	0.841	.001	29	view →
SARC	DFS	Tertile	All	0.430	0.708	.002	22	view →
THYM	DFS	Quartile	All	0.949	0.622	<.001	19	view →
KIRP	DFS	Tertile	IV	0.114	0.667	.021	18	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 26 lineages.

BMT2–MESO (OS)

Open the MESO breakdown →